Nov 8 2021

Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves

By |2021-11-07T19:56:42-05:00November 8th, 2021|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, November 8, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to radio frequency waves.  Previously, Halberd filed a provisional patent application on this treatment method.  Halberd believes this treatment would be effective against all SARS-CoV-2 variants, and this application preserves Halberd’s ...

Jul 28 2021

Halberd Corporation Successfully Establishes Disease Eradication Proof-of-Concept – “Never Before Accomplished”

By |2021-07-27T17:35:26-04:00July 28th, 2021|Featured, Investor News, News|0 Comments

A Major Step Towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer’s Disease/PTSD/CTE Jackson Center, PA, July 28, 2021 – Halberd Corporation (OTC-PINK: "HALB") establishes “proof of concept” taking a major step towards the elimination of multiple infectious diseases, such as, malaria, tuberculosis, sepsis, meningitis, and pandemics, among others, by successfully eliminating ...

Jul 22 2021

Halberd Corp. Advances the Elimination of Antigens Present in Alzheimer’s Disease & PTSD/Chronic Traumatic Encephalopathy

By |2021-07-21T19:48:45-04:00July 22nd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, July 22, 2021 – Halberd Corporation (OTC-PINK: "HALB") confirms the shipment of samples of metallic nanoparticles conjugated to Alzheimer’s Disease (AD) antibodies, Tau and Phosphorylated Tau.  Having successfully conjugated the metallic nanoparticles (via its breakthrough patent-pending process), GreenBioAZ shipped the materials to Youngstown State University (YSU).  At YSU, Dr. William G. Sturrus, ...

Jun 9 2021

Halberd Corporation Undertakes Process Toward the Elimination of Alzheimer’s Disease

By |2021-06-08T21:47:47-04:00June 9th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, June 9, 2021 – Halberd Corporation (OTC-PINK: "HALB") commences experimentations to eradicate three of the principal components of Alzheimer’s Disease.  By eliminating these three critical antigens, which form the basis for neurofibrillary tangles in the brain, Halberd believes that its patented extracorporeal treatment process can slow or stop the progress of the ...

May 25 2021

Halberd Corporation Successfully Conjugates Metallic Particles and E. Coli Antibody

By |2021-05-24T21:12:58-04:00May 25th, 2021|Featured, Investor News, News|0 Comments

Breakthrough Achievement Enables Extracorporeal Eradication of Pathogens Via Radio Frequency Waves and/or Laser Emissive Energy Jackson Center, PA, May 25, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful conjugation of gold-coated iron nanoparticles with an available E.coli antibody.  This milestone is a result of the Halberd sponsored research being conducted at GreenBioAz by Dr. ...

May 17 2021

Halberd Corporation Reports Successful Conjugation of Metallic Particles & SARS-CoV-2 Proprietary Monoclonal Antibody

By |2021-05-17T11:12:47-04:00May 17th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 17, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful conjugation of gold-coated iron nanoparticles with Halberd’s patent-pending monoclonal antibody against the SARS-CoV-2 spike protein.  This milestone paves the way for testing to proceed on the elimination of disease through the application of extracorporeal radio frequency waves or laser emissive energy ...

May 13 2021

Halberd Corporation Begins Testing of Patented Process for Laser Eradication of Disease

By |2021-05-12T20:19:30-04:00May 13th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 13, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the commencement of its patented extra-corporeal process experimentation using lasers to eradicate disease.  This technology facilitates disease eradication without the side-effects normally associated with conventional internal medications.  The experimentation is now being conducted at Youngstown State University (YSU) under the direct supervision of ...

Apr 19 2021

Halberd Corporation Moves Radio Frequency (RF) Disease Elimination Effort Forward With the Addition of Youngstown State University (YSU) and Dr. William G. Sturrus

By |2021-04-18T21:39:58-04:00April 19th, 2021|Featured, Investor News, News, Uncategorized|0 Comments

Brings Critical Radio Frequency Wave Expertise to Company’s Effort Jackson Center, PA, April 19, 2021 – Halberd Corporation (OTC-PINK: "HALB") is pleased to announce Youngstown State University’s (YSU) Dr. William G. Sturrus will lead the Radio Frequency (RF) research on Halberd’s Disease Elimination multi-organization Task Force.  Dr. Sturrus, who has 30 years of radio ...

Go to Top